|Bid||14.95 x 0|
|Ask||15.00 x 0|
|Day's Range||14.90 - 15.20|
|52 Week Range||12.65 - 17.10|
|PE Ratio (TTM)||-9.23|
|Earnings Date||Nov 8, 2017 - Nov 13, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||12.65|
Acer Therapeutics, a three-year-old Cambridge biotech developing drugs for ultra-rare diseases, said Monday that it will go public through a reverse merger with a small Texas company. Acer said it would merge with Opexa Therapeutics (OPXA), which laid off all but two of its 20 employees after its lead drug for multiple sclerosis flunked a mid-stage trial in October. In connection with the deal, Acer said it would receive a $15.7 million round of financing led by TVM Capital, a life sciences venture firm based in Germany.
After consummation Opexa's name will be changed to Acer Therapeutics Inc.
PARIS, May 19, 2017 /PRNewswire/ -- Acer (TWSE: 2353, LSE: ACID) has been named Official Partner of the Red Bull Kumite 2017 international fighting games competition, where the world's top Street Fighter ...